Enanta Pharmaceuticals (ENTA) Net Cash Flow Growth (5y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Enanta Pharmaceuticals | 367.22 Mn | 203.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.15% |
| Dec 31, 2025 | 16.66% |
| Sep 30, 2025 | 0.33% |
| Jun 30, 2025 | -21.09% |
| Mar 31, 2025 | -20.39% |
| Dec 31, 2024 | 31.89% |
| Sep 30, 2024 | 15.26% |
| Jun 30, 2024 | -18.62% |
| Mar 31, 2024 | -5.70% |
| Dec 31, 2023 | -44.70% |
| Sep 30, 2023 | -19.70% |
| Jun 30, 2023 | 23.73% |
| Mar 31, 2023 | 96.73% |
| Dec 31, 2022 | -22.38% |
| Sep 30, 2022 | -18.48% |
| Jun 30, 2022 | -38.16% |
| Mar 31, 2022 | -110.45% |
| Dec 31, 2021 | 59.61% |
| Sep 30, 2021 | 53.08% |
| Jun 30, 2021 | -18.10% |
| Mar 31, 2021 | 16.82% |
| Dec 31, 2020 | -27.03% |
| Sep 30, 2020 | -54.35% |
| Jun 30, 2020 | 44.59% |
| Mar 31, 2020 | 49.96% |
| Dec 31, 2019 | -54.84% |
| Sep 30, 2019 | -64.20% |
| Jun 30, 2019 | -27.95% |
| Mar 31, 2019 | 18.29% |
| Dec 31, 2018 | 34.25% |
| Sep 30, 2018 | 32.85% |
| Jun 30, 2018 | 15.15% |
| Mar 31, 2018 | -15.11% |
| Dec 31, 2017 | -25.30% |
| Sep 30, 2017 | 45.97% |
| Jun 30, 2017 | 16.89% |